Home

Differential
Counter

Flow
Tutorial

 

 
 
Myeloproliferative
neoplasms
Neoplasms with eosinophilia
(PDGRA/PDGFRB/FGFR1)
MDS/MPN MDS AML Acute leukemia
ambiguous lineage
Precursor lymphoid
neoplasms
Mature B cell
neoplasms
Mature T and NK
neoplasms
Hodgkin
lymphoma
Immunodeficiency associated
lymphoproliferative disorders
Histiocytic and dendritic
cell neoplasms
 

B Lymphoblastic Leukemia/Lymphoma

  Unusual antigen expression abstracts Prognostic abstracts Cytogenetic abstracts Antigen chart
B lymphoblastic leukemia / lymphoma, NOS
B lymphoblastic leukemia / lymphoma with recurrent genetic abnormalities
T lymphoblastic leukemia / lymphoma
Article Notes
Favorable
Hyperdiploidy (>50 chromosomes)
Treatment of Acute Lymphoblastic Leukemia.  
t(12;21)(p13;q22) (TEL-AML1)
Treatment of Acute Lymphoblastic Leukemia.  
Trisomy 4, 10, and 17
Treatment of Acute Lymphoblastic Leukemia.  
Unfavorable
Hypodiploidy (<45 chromosomes)  
Treatment of Acute Lymphoblastic Leukemia.  
t(4;11)(q21;q23) (MLL-AF4)
Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.  
Treatment of Acute Lymphoblastic Leukemia.  
t(9;22) (BCR-ABL)
Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.  
Treatment of Acute Lymphoblastic Leukemia.  
Additional miscellaneous studies
CD20 expression
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.  
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. CD20
Ph, t(4;11(q21;q23), t(8;14)(q24.1;q32), complex, hypodiploidy, triploidy, hyperdiploidy, del(9p), others
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.